This design template pertains to the Open-Label, Randomized, Phase 3 Clinical Trial of Venetoclax in Combination with a Hypomethylating Agent at a 28-Day or 14-Day Schedule in Patients with Newly Diagnosed Acute Myeloid Leukemia.